20/20 Biolabs, Inc. AIDX
0.22 USD +0.03 (+13.75%)
At closeNov 11, 2026, 4:05 PM EST
0.22 0.00 0.00%
After hours · Nov 11, 4:05 PM ET
0.191 Day range 0.2249
0.18 52-week range 50.00
- YTD
- -99.07%
- 1 year
- -99.07%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Nordicus Partners (NASDAQ:NORD) stock increased by 10.8% to $4.5 during Tuesday's after-market session. The market value of their outstanding shares is at $71.5 million. Gelteq (NASDAQ:GELS)…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock rose 34.9% to $2.94 during Thursday's after-market session. The market value of their outstanding shares is at $7.6 million. Senti Biosciences…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market session. The market value of their outstanding shares is at $3.9 million. Bullfrog AI Hldgs…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million. Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4%…
benzinga.com 20/20 Biolabs Q2 EPS $(0.26) Misses $(0.06) Estimate, Sales $730.571K Miss $891.000K Estimate 20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.06) by 333.33 percent. This is a 52.94 percent decrease over losses of…
benzinga.com 20/20 BioLabs Mulls Merger, Acquisition, Licensing, JV, Commercial Collaborations Across East Asia Under Its Roll-Up Strategy 20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic
benzinga.com BioLabs Announces Standstill Agreement With Streeterville Capital Regarding Outstanding Series E Convertible Preferred Stock, Effective July 16 Under the terms of the Agreement, during the 120-day period beginning on the date of the Agreement, Streeterville has agreed not to convert any shares of Series E Preferred Stock into shares of the…
benzinga.com Why Super Micro Computer Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket Shares of Super Micro Computer Inc (NASDAQ: SMCI) rose after reporting record backlog of $60B+ in orders and expected $11-12.5B in Q4 revenue. Gainers include INLIF Ltd, China SXT Pharma, Core AI…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com 10 Health Care Stocks Moving In Monday's Pre-Market Session 
benzinga.com Why Tower Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket Tower Semiconductor (TSEM) jumped 4.7% in pre-market trading after announcing a multi-year supply agreement and resolving IP disputes. Other gainers include VS Media Holdings (VSME), Freecast Inc…- benzinga.com U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com 20/20 Biolabs' OneTest Multi-Cancer Early Detection Blood Test Selected As Part Of Firefighter Cancer Screening Initiative For State Of Vermont In Partnership With National Diagnostic Services Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First CohortGAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20…- benzinga.com 20/20 Biolabs Q1 EPS $(0.28) Misses $(0.10) Estimate, Sales $353.375K Miss $779.000K Estimate 20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.10) by 180 percent. This is a 75 percent decrease over losses of $(0.16)…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com 20/20 BioLabs Strikes Agreement With University Of South Carolina for Commercialization of Patented Algorithm To Evaluate Changes In Prostate-Specific Antigen Levels 20/20 BioLabs, Inc. ("20/20") (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases,…- benzinga.com Maxim Group Initiates Coverage On 20/20 Biolabs with Buy Rating, Announces Price Target of $5 Maxim Group analyst Michael Okunewitch initiates coverage on 20/20 Biolabs (NASDAQ:AIDX) with a Buy rating and announces Price Target of $5.
- benzinga.com 20/20 BioLabs Says Its OneTest For Cancer Is Now Available Through Evexia Diagnostics Platform Joint Release Expands 20/20 BioLabs' Testing Solutions Across Evexia's Network of ~40,000 Functional and Integrative Medicine PractitionersMarks a Commercial Expansion Milestone for OneTest for…
- benzinga.com 20/20 Biolabs FY EPS $(0.76) Up From $(1.16) YoY, Sales $2.045M Up From $1.752M YoY 20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.76) per share. This is a 34.48 percent increase over losses of $(1.16) per share from the same period last year. The company reported…
benzinga.com 20/20 BioLabs Secures $520K MDH Grant To Deploy OneTest MCED Blood Test Across Maryland Fire Departments State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc.…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com What's Going On With 20/20 Biolabs Stock? Shares of 20/20 Biolabs, Inc. (NASDAQ: AIDX) are trading lower Tuesday after the company announced that it entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare.- benzinga.com 20/20 BioLabs Partners With ROKIT To Add AI-Driven Kidney Disease Risk And Biomarker Insights To Longevity Platform Inflammatory Biomarker Tracking Predicted to Enhance Response to 3-D Bio-Printed TherapiesExpands OneTest for Longevity with Chronic Kidney Disease Risk AssessmentGAITHERSBURG, Md., March 24, 2026…
benzinga.com 20/20 BioLabs Provides Update On Patented PTM Based, Machine Learning Derived Multi-Cancer Early Detection Methodology In Light Of Recent Studies 20/20 BioLabs (NASDAQ:AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today provided an…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com 20/20 BioLabs Announces Launch And Commercial Availability Of OneTest For Longevity Solution, Built With IBM AI Capabilities Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session